MediWound Ltd. is a biotechnology niche specialty company. Established in 2001, MediWound is focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management.
MediWound’s goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™.
NexoBrid™, is indicated in Europe for removal of eschar in adults with deep partial- and full-thickness thermal burns.
NexoBrid™ successfully completed clinical development in hospitalized burn wounds and was launched throughout Europe.
MediWound operates a cGMP and ISO13485 manufacturing facility for sterile pharmaceutical products and medical devices that meets high quality requirements.
MediWound’s innovative drug, NexoBrid™, was approved in December 2012 by EMA via a centralized procedure and was granted orphan indication for removal of eschar in adults with deep partial- and full-thickness thermal burns (also known as debridement)